Pomerantz Law Firm Announces the Filing of a Class Action Against AeroVironment, Inc. and Certain Officers

AeroVironment (AVAV) is facing a securities class action alleging misleading statements about the Space Force’s SCAR program after the government issued a stop-work order. Subsequent disclosures drove sharp stock declines: -15.77% to $330.89 on Jan 20, 2026, -17.42% to $208.32 on Mar 2, 2026, and -6.24% to $207.73 on Mar 11, 2026. The company also reported a Q3 FY2026 operating loss of $179.0M, including a $151.3M goodwill impairment tied to the SCAR stop-work and contract termination, and it would need to recompete for the program.

Analysis

This is less a litigation headline than a reset in how the market should underwrite the equity story: a defense tech name with a concentrated, government-dependent growth narrative just lost the key assumption supporting its premium multiple. When a program shifts from sole-source bespoke work to a competitive, lower-cost framework, the economic value migrates away from the incumbent toward whoever can deliver acceptable capability at lower price and faster procurement cadence; that is margin-negative for the former first mover and usually multiple-negative for any acquisition-backed growth story.

The second-order risk is broader than AVAV. Any defense tech company leaning on one or two “transformational” programs, especially after a stock-funded acquisition, now screens as more vulnerable to reprocurement and write-down risk. The market will start discounting backlog quality, not just backlog size, and that tends to hit names with high goodwill, thinner free cash flow, and less pricing power first. In contrast, larger primes and COTS-oriented vendors should benefit from a procurement environment that favors diversification and lower unit cost.

Near term, the class action is mostly an overhang amplifier; the fundamental catalyst is the government’s acquisition path, which can still reverse the stock only if AVAV regains a durable role with economics close to the original plan. Over 1-3 months, watch for guidance cuts, margin compression, or any additional impairment language; over 6-18 months, the key question is whether this becomes a template for other sole-source defense programs. The thesis is falsified if AVAV wins back a materially sized award on terms that preserve incremental margin and backlog visibility.

Key Decisions for Investors

• Short AVAV on any 1-2 day relief rally; treat this as a 1-3 month earnings/multiple de-rating trade, not a one-day litigation scalp. Invalidated if management announces a replacement award with clear revenue/margin visibility.
• Prefer a 3-6 month AVAV put spread over outright puts if implied volatility is elevated; the cleaner expression is continued multiple compression from lower program visibility, with roughly 2:1 downside payoff if the stock reprices another 15-20%.
• Pair trade: long NOC or LMT / short AVAV to isolate company-specific procurement risk while staying neutral-to-bullish on defense budgets. This is the cleaner expression if the goal is to hedge market beta and own quality visibility.
• Set an alert for any new SCAR-related award, amendment, or guidance update. If the company restores program economics or reverses the impairment narrative, cover the short immediately; that would be the strongest falsifier.